Early Onset Alzheimer's Disease Genomic Study

Completed

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your DNA and RNA in order to help doctors diagnose, treat, and monitor people at risk of developing Early-Onset AD in the future.

Key facts

Study ID

NCT03645993

Run by

Baylor Research Institute

People needed

26

Starts

2017-06-16

Expected to finish

2024-04-24

Last updated by the study team

2026-02-12

Who can join

Age: 40 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of early-onset Alzheimer's disease based on the NIA-AA diagnostic criteria as determined by the clinician. (Those patients with severe dementia due to Alzheimer's disease or who have impaired decisional capacity, may participate only if their legally authorized representative gives their consent.)
• Male and female patients ≥40 and ≤65 years of age.
• Parents and siblings of the participant with Alzheimer's disease.

You may not qualify if…

• Family history of early or late-onset Alzheimer's disease.
• Uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal informed consent

Where it is running

• Baylor Scott & White AT&T Memory Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.